New UK consensus guidelines have clarified the immediate clinical response required for tissue filler-induced vision loss (TFIVL), a rare but catastrophic complication of dermal filler injections that demands urgent recognition and rapid escalation to specialist care.
The guidance is broadly aligned with Australia’s 2024 Guideline for Filler Blindness from the Royal Australian and New Zealand College of Ophthalmologists, which likewise emphasises early recognition, urgent referral and the primacy of prevention.
Published in Aesthetic Surgery Journal and developed by a multidisciplinary steering group, including Australia’s Prof Greg Goodman and Mike Clague, the UK guidelines outline a structured, time-critical protocol designed to maximise the chance of restoring retinal blood flow while reinforcing prevention as the primary safeguard.
TFIVL most commonly occurs when filler material enters the arterial system and embolises to the ophthalmic or retinal circulation. Once visual disturbance occurs, irreversible damage can develop within minutes. The consensus document therefore places strong emphasis on immediate cessation of treatment, early intervention and rapid referral pathways.
The consensus statement emphasises that TFIVL should be treated as a medical emergency, not a delayed or watch-and-wait complication.
UK guidelines: key takeaways
Immediate recognition and cessation
Clinicians are advised to immediately stop injecting if patients report sudden severe pain, blanching of the skin, visual disturbance or vision loss. These signs should trigger emergency protocols without delay.
The guidelines state that continuing treatment or monitoring symptoms without escalation is inappropriate once these warning signs appear.
Emergency preparedness in clinic
All practitioners performing dermal filler injections are advised to maintain a clearly defined emergency kit, including hyaluronidase and aspirin, that is immediately accessible during procedures.
The availability of hyaluronidase is considered essential when using hyaluronic acid fillers, even though outcomes following vision loss remain unpredictable. Emergency preparedness is framed as a core professional responsibility rather than an optional safeguard.
Non-invasive first-response measures
The consensus outlines several immediate, non-invasive techniques aimed at restoring retinal blood flow:
- Ocular massage, applying firm pressure to the closed eye in cycles of five seconds on and ten seconds off over five-minute intervals
Hypercapnia, achieved by paper-bag rebreathing to increase carbon dioxide levels and potentially dilate retinal arteries.
These measures are intended as early first-response interventions while urgent referral is arranged.
Pharmacological intervention
Oral aspirin, commonly 325 mg twice daily where not contraindicated, is recommended to reduce platelet aggregation and minimise further thrombotic propagation.
For hyaluronic acid fillers, hyaluronidase may be administered in an attempt to dissolve the embolised material. The guidelines acknowledge that evidence for effectiveness once vision loss has occurred is limited and variable, but early administration remains part of recommended practice.
Rapid transfer to specialist care
Urgent transfer to an emergency department or ophthalmology service is central to the guidance. Specialist management may include advanced interventions such as hyperbaric oxygen therapy, depending on timing and clinical presentation.
The consensus makes clear that in-clinic management alone is insufficient and that delays in escalation significantly worsen prognosis.
Prevention, anatomy and consent
Beyond emergency response, the guidelines reinforce prevention as the most effective safeguard. Detailed knowledge of facial vascular anatomy, particularly in high-risk injection zones with known anastomoses to the ophthalmic circulation, is highlighted as essential.
Informed consent processes must also explicitly address the rare but serious risk of permanent vision loss, ensuring patients understand the potential severity of complications before treatment.
Although TFIVL is uncommon, its consequences are profound. While evidence remains limited, these guidelines establish a practical framework for aesthetic clinicians across the UK and may serve as a model for other healthcare systems.
